Profile data is unavailable for this security.
About the company
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.
- Revenue in CAD (TTM)353.72k
- Net income in CAD399.81k
- Incorporated2011
- Employees1.00
- LocationReplicel Life Sciences Inc570 Granville St Suite 900VANCOUVER V6C 3P1CanadaCAN
- Phone+1 (604) 248-8693
- Fax+1 (604) 248-8730
- Websitehttps://www.replicel.com/